Assessing risk factors: prevention of inhibitors in haemophilia.
about
Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of HemophiliaPast, present and future of hemophilia: a narrative review.Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.Non-genetic risk factors and their influence on the management of patients in the clinic.Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.Successful eradication of inhibitor of late recurrence and other high risk prognostic factors in a patient with severe haemophilia A.Partnering to change the world for people with haemophilia: 7th Haemophilia Global Summit, Madrid, Spain 22-24 September 2016.Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction.Haemophilia and joint disease: pathophysiology, evaluation, and management.
P2860
Q34424570-5669797E-23F6-4D66-870F-B17DC01E4247Q36085401-664030AC-E85C-4275-BC97-EC5DCAD6ED5CQ36196486-584222EF-4A83-4FB3-94A7-D31FAEBA4553Q38007018-DDF33D44-645E-4F96-BE33-A28BA2F379B6Q38056462-097A9426-4C81-4840-A99D-04C288A66F0DQ38308194-3B336302-239A-4DB0-9973-532735BFD5FEQ41592459-2FF2A044-CF63-40FA-AA6C-C0F2CF64C470Q41917020-3D0B2F0F-1FFB-40E4-8377-E829DFFAA689Q42408107-0924D5AC-6362-4993-9A17-FF0A5AD92AD9Q45856587-074796D0-7EE1-4772-8055-7867EE379335Q45870476-2B17C0B4-85A9-467E-86A1-43BCE3475D4FQ45872095-2F803736-58D9-43A2-B1A4-B4A7F6D0FC2CQ45879318-467411E6-BD8B-4E67-9694-1A4C69B99200Q55004994-B23B37D1-3615-4184-8913-951429673888
P2860
Assessing risk factors: prevention of inhibitors in haemophilia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Assessing risk factors: prevention of inhibitors in haemophilia.
@en
Assessing risk factors: prevention of inhibitors in haemophilia.
@nl
type
label
Assessing risk factors: prevention of inhibitors in haemophilia.
@en
Assessing risk factors: prevention of inhibitors in haemophilia.
@nl
prefLabel
Assessing risk factors: prevention of inhibitors in haemophilia.
@en
Assessing risk factors: prevention of inhibitors in haemophilia.
@nl
P2860
P1433
P1476
Assessing risk factors: prevention of inhibitors in haemophilia.
@en
P2093
H Chambost
P2860
P356
10.1111/J.1365-2516.2009.02197.X
P478
16 Suppl 2
P577
2010-03-01T00:00:00Z